AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$CYTK

Blum Robert I sold $472K of CYTK

Blum Robert I (President & CEO) sold 7,500 shares of CYTOKINETICS INC (CYTK) at $62.88 ($0.47M total) on 2026-10-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Blum Robert I
Published Oct 13, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 8:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CYTK
Bearish
medium confidence
Mentioned
$CYTK
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYTKBearishLow
01

Why it matters

The disclosed sale adds new information about insider sentiment, which can affect short‑term price action.

02

Market read

New insider sale provides fresh data for traders; likely modest downside pressure.

03

What to watch

Potential pre‑arranged 10b5‑1 plan reduces negative signal strength.

Relevance 3/10Novelty 3/10Timing: post‑market filing

Background

Form 4 filings disclose insider transactions; a sale by the CEO is noteworthy for traders.

Company-level read

Ticker impact

$CYTKBearishMedium confidence
Context

President & CEO Robert Blum sold 7,500 shares for $471,600 on 2026-10-12 via a Form 4 filing.

Expected impact

likely downward pressure as the market prices in the insider sell

Evidence & confidence

A C‑suite insider sold a sizable block at $62.88 per share; such sales often trigger short‑term selling pressure.

Market effects

Sector

Minimal; biotech sector may see slight sentiment drag from insider activity.

Regional

None

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • person
    Robert Blum

    President & CEO of Cytokinetics Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CYTK insider trading history →

Related articles

$CYTKMedAI 8/10

Cytokinetics Q3 Earnings Call Highlights

Cytokinetics reported Q3 revenue of $47.6M, up from $1.9M YoY, driven by MYQORZO sales. Net loss narrowed to $190.1M. Aficamten met primary endpoints in Phase 3 trial, with EU submission planned for 2027. Company reaffirmed 2026 expense guidance and discussed pipeline milestones.

finance.yahoo.com
$CYTKMedAI 8/10

Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update

CYTOKINETICS INC (CYTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business Update MYQORZO ® (aficamten) Net Product Revenue of $44.5 Million Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive HCM in Q4 2026 and Type II Variation in the European U

SEC EDGAR 8-K